• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP ANTI-HBS2 (AHBS2) ASSAY; AHBS2 IMMUNOASSAY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP ANTI-HBS2 (AHBS2) ASSAY; AHBS2 IMMUNOASSAY Back to Search Results
Model Number N/A
Device Problem No Apparent Adverse Event (3189)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 12/05/2018
Event Type  malfunction  
Manufacturer Narrative
This is a case of one patient sample resulted (b)(6) with advia centaur xp anti-hbs2 reagent lot 119098.However, obtained (b)(6) result with repeat testing using the same sample tube.Patient is (b)(6) with (b)(6) biomarkers.There is no indication of patient receive (b)(6) vaccination.Additionally, there was no evidence of fibrin in the sample.The customer service engineer (cse) was at the customer site investigating another issue.The cse decontaminated the analyzer and determined contamination tests are okay.Post-service, a (b)(6) result was obtained upon repeating the affected patient sample with anti-hbs2 assay.Based on the information available, there may have been non-specific interference between sample and reagent giving (b)(6) result.The advia centaur xp anti-hbs2 ous instruction for use (ifu) (10629819_en rev.K, 2017-12) states under interpretation of results section "nonreactive: samples with an initial value of less than 8 miu/ml are considered nonreactive (negative) for antibodies to hbsag." further repeat testing is not required as per assay ifu.Review of in-house data shows the performance of lot 119098 met all release criteria.The instrument is performing within specifications.No further evaluation of the device is required.
 
Event Description
A (b)(6) result was obtained for a patient sample upon repeat.The initial result was (b)(6) and the second replicate of the repeat testing was (b)(6).The (b)(6) result was reported to the physician.Patient treatment was not prescribed or altered.There was no report of adverse health consequences due to the (b)(6) results.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ADVIA CENTAUR XP ANTI-HBS2 (AHBS2) ASSAY
Type of Device
AHBS2 IMMUNOASSAY
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
333 coney street
e. walpole MA 02032
Manufacturer Contact
eiman sulieman
333 coney street
e. walpole,, MA 02032
5086604603
MDR Report Key8199452
MDR Text Key132388778
Report Number1219913-2018-00306
Device Sequence Number1
Product Code LOM
UDI-Device Identifier00630414561790
UDI-Public00630414561790
Combination Product (y/n)N
Reporter Country CodeIT
PMA/PMN Number
P100039
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 12/27/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date07/26/2020
Device Model NumberN/A
Device Catalogue Number10286268
Device Lot Number65758098
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/11/2018
Initial Date FDA Received12/27/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age69 YR
-
-